Table 3 Comparison of the parameters of lipid and glucose metabolism, hepatic function and muscle damage in the diet therapy and diet-plus-statin groups
From: Effects of pitavastatin add-on therapy on chronic kidney disease with albuminuria and dyslipidemia
| Â | Diet | Diet-plus-statin | ||||
|---|---|---|---|---|---|---|
| Â | Baseline | 6Â months | 12Â months | Baseline | 6Â months | 12Â months |
Lipid metabolism: | Â | Â | Â | Â | Â | |
 TC (mg/dL) | 211 ± 6 | 220 ± 9 | 201 ± 6 | 207 ± 7 | 171 ± 5**†| 157 ± 5**††|
 LDL-C (mg/dL) | 139 ± 6 | 139 ± 7 | 126 ± 5 | 136 ± 6 | 94 ± 4**†| 83 ± 4**††|
 HDL-C (mg/dL) | 56 ± 3 | 57 ± 4 | 56 ± 4 | 56 ± 4 | 61 ± 5 | 57 ± 5 |
 TG (mg/dL) | 145 ± 14 | 198 ± 33 | 149 ± 21 | 154 ± 20 | 132 ± 19 | 122 ± 18 |
Glucose metabolism: | Â | Â | Â | Â | Â | |
 Glucose (mg/dL) | 113 ± 7 | 108 ± 4 | 115 ± 7 | 107 ± 4 | 108 ± 4 | 115 ± 9 |
 HbA1C (%) | 5.6 ± 0.1 | 5.6 ± 0.2 | 5.5 ± 0.2 | 5.6 ± 0.1 | 5.7 ± 0.1 | 5.6 ± 0.2 |
Hepatic and muscle enzymes: | Â | Â | Â | Â | ||
 AST (U/L) | 24 ± 1 | 27 ± 2 | 27 ± 2 | 20 ± 1†| 26 ± 5 | 22 ± 2 |
 ALT (U/L) | 22 ± 2 | 25 ± 2 | 24 ± 3 | 20 ± 3 | 29 ± 8 | 26 ± 6 |
 CK (U/L) | 110 ± 13 | 128 ± 20 | 161 ± 54 | 106 ± 13 | 131 ± 24 | 114 ± 16 |